Panelists discuss the recommendations for identifying, evaluating, and managing neurological toxicities, including workup and ...

Dr Graff discusses the recommendations for identifying, evaluating, and managing neurological toxicities, including workup ...

For decades, the medical world has avidly searched for groundbreaking treatments against one of humanity’s most resilient ...

OCT for early diagnosis and characterization of dermatologic adverse events to oncologic drugs and correlation to ...

Nectin-4 is a cell-adhesion molecule overexpressed in several tumor types, including breast, ovarian, lung, colorectal, pancreatic and urothelial cancer. Enfortumab vedotin (EV), an anti-Nectin-4 ...

Typically, the problems that veterinarians see associated with the day are gastrointestinal issues as your dog is ...

Cash, cash equivalents, and marketable securities of $360.1 million at Q3 2024 - CARLSBAD, Calif., Nov. 7, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical ...

The following is a summary of “Prevalence and outcomes of cancer and treatment-associated toxicities for patients with Ataxia Telangiectasia,” published in the November 2024 issue of Allergy and ...

A CD70-targeted CAR T-cell therapy for advanced kidney cancer continued to show durable activity in treatment-refractory ...

Stock-based compensation decreased by approximately $340 thousand in the three months ended September 30, 2024, compared to the three months ended September 30, 2023, primarily due to stock options ...

FDA approves Autolus Therapeutics' Aucatzyl for adults with relapsed or refractory B-cell precursor acute lymphoblastic ...

Preliminary results from Phase 1 ACESOT-1051 trial of WEE1 inhibitor, APR-1051, demonstrate the product to be well-tolerated with no unexpected ...